ArticleFrontiers in immunology2025
Melanoma causes phenotypic modulations and metabolic switches of iNKT cells influencing clinical outcomes.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Invariant NKT (iNKT) cells are crucial effectors in cancer immunosurveillance, due to their immunomodulatory potential through a broad range of effector and regulatory functions. Yet, their use as targets or vectors for cancer immunotherapy in cancer yielded inconsistent outcomes, due to potential tumor immune escape mechanisms. Limited information is available regarding the potential dysfunctions of iNKT cells in melanoma patients, and their clinical significance. A better understanding of iNKT cell biology and subversion in these patients would help designing new immunotherapies and improving clinical translations. Methods: Here, we depicted extensive phenotypic, metabolic and functional features of circulating and tumor-infiltrating iNKT cells in melanoma patients, and assessed their clinical relevance. Results: We observed that iNKT cells infiltrated melanoma tumors in a gender- and site-dependent manner, and were associated with poor clinical outcome. Invariant NKT cells exhibited a higher basal activation status together with a skewed expression of NK receptors (NKR), NKG2 and immune checkpoints (ICP), as well as a shift toward regulatory iNKT (iNKTreg) cell profile in the melanoma microenvironment. We identified LAG3, CTLA4 and TIM3 as critical negative prognosis factors of clinical evolution. Moreover, tumor-infiltrating iNKT cells displayed a dampened metabolic activity with a decreased glycolysis dependency; such perturbed energetic metabolism impacted patient clinical outcome. Furthermore, iNKT cells revealed distinct metabolic profiles depending on their activation status and ICP profile, underlining critical connections between iNKT cell features and metabolic pattern. Discussion: Overall, our study reveals major phenotypic and metabolic disturbances of circulating and tumor-infiltrating iNKT cells in melanoma, with clinical impacts. By unveiling new key features and skewing details on iNKT cells in melanoma, our study paves the way for innovative combination strategies exploiting metabolic pathways and/or disturbed ICP profiles to overcome immune subversion and better harness the potential of iNKT cells for cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.